Vazyme Biotech Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Public

  • Employees
  • 2,637

Employees

  • Stock Symbol
  • 688105

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $2.80
  • (As of Friday Closing)

Vazyme Biotech General Information

Description

Nanjing Vazyme Biotech Co Ltd is a biotechnology company. It is committed to research and development both in technology and products focusing on functional proteins, such as enzymes, antigens, antibodies, and polymer organic materials.

Contact Information

Website
www.vazyme.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Building C2, Hongfeng Science and Technology Park
  • Kechuang Road, Nanjing Economic and Technological Development Zone
  • Nanjing, Jiangsu
  • China
+86 025
Primary Industry
Biotechnology
Other Industries
Discovery Tools (Healthcare)
Diagnostic Equipment
Stock Exchange
SHG
Vertical(s)
Life Sciences
Corporate Office
  • Building C2, Hongfeng Science and Technology Park
  • Kechuang Road, Nanjing Economic and Technological Development Zone
  • Nanjing, Jiangsu
  • China
+86 025

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Vazyme Biotech Stock Performance

As of 24-Jan-2025, Vazyme Biotech’s stock price is $2.80. Its current market cap is $1.13B with 402M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.80 $2.79 $2.39 - $4.14 $1.13B 402M 1.75M

Vazyme Biotech Financials Summary

As of 30-Sep-2024, Vazyme Biotech has a trailing 12-month revenue of $195M.

In Thousands,
USD 		TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 1,126,187 1,508,566 2,717,934 6,498,697
Revenue 195,401 181,768 529,952 289,392
EBITDA (2,196) 3,445 107,012 127,057
Net Income 3,286 (10,029) 88,238 105,046
Total Assets 698,413 810,622 870,409 722,788
Total Debt 94,125 181,562 66,404 14,305
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Vazyme Biotech Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Vazyme Biotech‘s full profile, request access.

Request a free trial

Vazyme Biotech Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion
Price		 % Owned

This information is available in the PitchBook Platform. To explore Vazyme Biotech‘s full profile, request access.

Request a free trial

Vazyme Biotech Patents

  • 10

    Total Documents Applications and Grants

  • Total Patents Families

  • 3

    Granted

  • 6

    Pending

  • Expiring in next 12 mo

Vazyme Biotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
DE-202022103176-U1 Sample access tube Active 09-Oct-2021
FR-3127897-A3 Sample access tube Active 09-Oct-2021
FR-3127897-B3 Sample access tube Active 09-Oct-2021
EP-4211158-A1 Neutralizing antibodies against sars-cov-2 Pending 14-Sep-2020
EP-4211159-A1 Neutralizing antibodies against sars-cov-2 Inactive 14-Sep-2020 A61K45/06
To view Vazyme Biotech’s complete patent history, request access »

Vazyme Biotech Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vazyme Biotech Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Vazyme Biotech‘s full profile, request access.

Request a free trial

Vazyme Biotech Investments (2)

Vazyme Biotech’s most recent deal was a Early Stage VC with Huiliao for . The deal was made on 14-Jan-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Huiliao 14-Jan-2025 Early Stage VC Pharmaceuticals
CYGENTA (China) 25-Oct-2022 Early Stage VC BPO/Outsource Services
To view Vazyme Biotech’s complete investments history, request access »

Vazyme Biotech ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Vazyme Biotech’s complete esg history, request access »

Vazyme Biotech FAQs

  • When was Vazyme Biotech founded?

    Vazyme Biotech was founded in 2012.

  • Where is Vazyme Biotech headquartered?

    Vazyme Biotech is headquartered in Nanjing, China.

  • What is the size of Vazyme Biotech?

    Vazyme Biotech has 2,637 total employees.

  • What industry is Vazyme Biotech in?

    Vazyme Biotech’s primary industry is Biotechnology.

  • Is Vazyme Biotech a private or public company?

    Vazyme Biotech is a Public company.

  • What is Vazyme Biotech’s stock symbol?

    The ticker symbol for Vazyme Biotech is 688105.

  • What is the current stock price of Vazyme Biotech?

    As of 24-Jan-2025 the stock price of Vazyme Biotech is $2.80.

  • What is the current market cap of Vazyme Biotech?

    The current market capitalization of Vazyme Biotech is $1.13B.

  • What is Vazyme Biotech’s current revenue?

    The trailing twelve month revenue for Vazyme Biotech is $195M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »